Nature Reviews Cardiology

Article	Citations
Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension	699
Interplay between inflammation and thrombosis in cardiovascular pathology	469
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease	459
PPAR control of metabolism and cardiovascular functions	434
Smart wearable devices in cardiovascular care: where we are and how to move forward	424
Artificial intelligence-enhanced electrocardiography in cardiovascular disease management	415
Global epidemiology of dyslipidaemias	411
Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases	378
Epidemiology of cardiovascular disease in Europe	356
Pathophysiology of sepsis-induced cardiomyopathy	329
Global epidemiology of valvular heart disease	320
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation	298
Transportation noise pollution and cardiovascular disease	284
Epicardial adipose tissue in contemporary cardiology	277
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis	264
Cellular and molecular pathobiology of heart failure with preserved ejection fraction	234
The role of cardiac rehabilitation in improving cardiovascular outcomes	224
Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes	224
Ceramides and other sphingolipids as drivers of cardiovascular disease	200
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium	199
Heart failure with mid-range or mildly reduced ejection fraction	191
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?	190
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging	182
Optical coherence tomography in coronary atherosclerosis assessment and intervention	180
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms	178

Systems biology in cardiovascular disease: a multiomics approach	172
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches	169
Vascular endothelial cell development and diversity	157
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	146
Sit less and move more for cardiovascular health: emerging insights and opportunities	145
Transforming growth factor-β in myocardial disease	138
Mechanisms and consequences of endothelial cell senescence	137
Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease	135
The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy	135
Blood pressure and its variability: classic and novel measurement techniques	134
Obesity and the risk of cardiometabolic diseases	130
The role of cellular senescence in cardiac disease: basic biology and clinical relevance	127
Epidemiology and prevention of venous thromboembolism	126
Genomics of hypertension: the road to precision medicine	119
High-density lipoproteins, reverse cholesterol transport and atherogenesis	118
Genomic frontiers in congenital heart disease	118
Apolipoproteins in vascular biology and atherosclerotic disease	117
Epidemiology and modifiable risk factors for atrial fibrillation	116
The role of mitochondrial fission in cardiovascular health and disease	114
Climate change and cardiovascular disease: implications for global health	114
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia	108
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development	107
Cardiac optogenetics: a decade of enlightenment	106
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	104
Applications of artificial intelligence in cardiovascular imaging	102
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention	99
Sulfide regulation of cardiovascular function in health and disease	98
Update on the pathophysiology and medical treatment of peripheral artery disease	98
Branched-chain amino acids in cardiovascular disease	92
Cardiovascular risks of climate change	88
RNA-targeting and gene editing therapies for transthyretin amyloidosis	87
Myocardial stunning and hibernation revisited	84
A fresh look at coronary microembolization	84
Clinical utility of polygenic risk scores for coronary artery disease	83
Bleeding avoidance strategies in percutaneous coronary intervention	82
Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes	82
Macrophages in cardiac remodelling after myocardial infarction	81
Cardiac involvement in the long-term implications of COVID-19	81
Social determinants of atrial fibrillation	81
Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions	79
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia	79
Prevention of atherosclerosis from childhood	77
Obstructive sleep apnoea heterogeneity and cardiovascular disease	75
Targeted delivery of therapeutic agents to the heart	75
Hallmarks of cardiovascular ageing	74
Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs	71
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies	70
Targeting the sarcomere in inherited cardiomyopathies	69
Immune cell profiling in atherosclerosis: role in research and precision medicine	65
Pharmacogenetics to guide cardiovascular drug therapy	63

Calcific aortic valve disease: mechanisms, prevention and treatment	62
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism	60
Electroimmunology and cardiac arrhythmia	59
The contribution of the exposome to the burden of cardiovascular disease	58
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective	58
The evolving cardiac lymphatic vasculature in development, repair and regeneration	57
The health digital twin: advancing precision cardiovascular medicine	54
Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges	53
Bioengineering approaches to treat the failing heart: from cell biology to 3D printing	52
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	52
Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research	51
The role of aldehyde dehydrogenase 2 in cardiovascular disease	51
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases	50
The microtubule cytoskeleton in cardiac mechanics and heart failure	49
Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease	48
The oral microbiome in the pathophysiology of cardiovascular disease	48
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	48
Sirtuins in atherosclerosis: guardians of healthspan and therapeutic targets	47
Cardiac fibroblasts and mechanosensation in heart development, health and disease	47
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention	46
Remote monitoring and digital health tools in CVD management	46
Towards precision medicine in heart failure	45
Hypertension in China: epidemiology and treatment initiatives	45
Repurposing drugs to treat cardiovascular disease in the era of precision medicine	44
Immune and inflammatory mechanisms in hypertension	43
Flow-induced reprogramming of endothelial cells in atherosclerosis	42
Single-cell transcriptomics for the assessment of cardiac disease	42
The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease	42
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	39
Increasing representation and diversity in cardiovascular clinical trial populations	39
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer	38
Improving clinical practice guidelines with implementation science	38
Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization	38
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure	38
Temporary mechanical circulatory support devices: practical considerations for all stakeholders	37
Interventional therapies for pulmonary embolism	36
Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome	36
Pathophysiology and risk factors of peripartum cardiomyopathy	33
Global epidemiology of acute coronary syndromes	32
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease	32
Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group	31
A change of heart: new roles for cilia in cardiac development and disease	31
The use of new CRISPR tools in cardiovascular research and medicine	30
Effects of fatty acids on T cell function: role in atherosclerosis	29
FGF23 and klotho at the intersection of kidney and cardiovascular disease	28
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	28
Current concepts and novel targets for antiplatelet therapy	28
Plastics and cardiovascular disease	27
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization	27
The need for increased pragmatism in cardiovascular clinical trials	26
Genetics and mechanisms of thoracic aortic disease	26
Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease	24
Cardiovascular health and disease in migrant populations: a call to action	24
The biology of atherosclerosis comes full circle: lessons for conquering cardiovascular disease	24
Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction	23
Long COVID and cardiovascular disease: a learning health system approach	23
A role for lipophagy in atherosclerosis	23
Trained immunity in atherosclerotic cardiovascular disease	23
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden	23
Cardiovascular physiology and pathophysiology at high altitude	22
RNA modifications in cardiovascular health and disease	20
Cardiovascular disease and cancer: shared risk factors and mechanisms	20
Atherosclerotic plaque stabilization and regression: a review of clinical evidence	20
PCSK9-targeted therapies: present and future approaches	19
2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease	19
Genomic enhancers in cardiac development and disease	19
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thro	19
The bidirectional association between atrial fibrillation and myocardial infarction	19
Clarification of the definition of hypoplastic left heart syndrome	18
Oxidized phospholipids in cardiovascular disease	18
Current and future applications of virtual reality technology for cardiac interventions	18
Genetics and genomics of arrhythmic risk: current and future strategies to prevent sudden cardiac death	18
Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets	17
Nanotherapeutics for cardiovascular disease	16
Clonal haematopoiesis and atherosclerosis: a chicken or egg question?	16
The ongoing quest for the first total artificial heart as destination therapy	14
Interplay of hypoxia-inducible factors and oxygen therapy in cardiovascular medicine	14
A pathophysiological compass to personalize antianginal drug treatment	14
Contemporary pharmacological treatment and management of heart failure	13
AIMing 2 treat atherosclerosis	13

The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis	13
A cardioimmunologist’s toolkit: genetic tools to dissect immune cells in cardiac disease	13
Invention and uptake of TAVI over the first 20 years	12
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries	12
Travelling with heart failure: risk assessment and practical recommendations	11
Strategies to prevent burnout in the cardiovascular health-care workforce	11
The future of cardiac xenotransplantation	11
Heart transplantation: advances in expanding the donor pool and xenotransplantation	10
The menopausal transition period and cardiovascular risk	10
Shaping the future of cardiovascular medicine in the new era of wearable devices	10
Cardiac splicing as a diagnostic and therapeutic target	10
Lipoprotein(a), platelet function and cardiovascular disease	9
Role of sex hormones in cardiovascular diseases	9
Immunomodulation and immunopharmacology in heart failure	9
The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction	9
Exosome-derived microRNAs improve cardiac function	9
Publisher Correction: Cellular and molecular pathobiology of heart failure with preserved ejection fraction	8
Efferocytosis in atherosclerosis	8
Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease	8
Animal models to study cardiac regeneration	8
Cardiovascular health concerns in sexual and gender minority populations	8
Piezo1 senses pressure overload and initiates cardiac hypertrophy	8
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure	8
Effects of lifestyle factors on leukocytes in cardiovascular health and disease	7
Detection of subclinical hypertrophic cardiomyopathy	7
Guidelines to lower intake of added sugar are necessary and justified	7
Publisher Correction: Reappraising the role of inflammation in heart failure	7
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course	7
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	7
A roadmap of strategies to support cardiovascular researchers: from policy to practice	7
Macrophages and neutrophils modulate arrhythmia risk after myocardial infarction	7
Uncertainties about left ventricular thrombus after STEMI	7
Universal flu vaccines: a shot at lifelong cardioprotection?	7
Author Correction: Epidemiology and modifiable risk factors for atrial fibrillation	6
Protein glycosylation in cardiovascular health and disease	6
Defining iron deficiency in patients with heart failure	6
Improving medication adherence in cardiovascular disease	6
Circadian medicine: a critical strategy for cardiac care	6
Collateral cardiovascular damage during the COVID-19 pandemic	6
Very high HDL-C levels are associated with higher mortality in patients with CAD	6
Targeting immune cell recruitment in atherosclerosis	5
Electron microscopy of cardiac 3D nanodynamics: form, function, future	5
Macropinocytosis promotes foam cell formation and atherosclerosis	5
The need for new clinical trials of old cardiovascular drugs	5
The dynamic cardiac cellular landscape: visualization by molecular imaging	5
Caffeine consumption and cardiovascular health	5
Sex-related similarities and differences in responses to heart failure therapies	5
A high-salt diet promotes atherosclerosis by altering haematopoiesis	5
Statins promote efferocytosis in atherosclerotic plaques	5
RNA-binding proteins in cardiovascular biology and disease: the beat goes on	5
A phoenix rises from the ashes of cardiac cell therapy	5
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease	5
Cardiovascular benefits of fermented foods and beverages: still up for debate	5
Preventing cardiac damage in patients with COVID-19	5
Stress and cardiovascular disease: an update	5
Human susceptibility to coronary artery disease: lessons from chimpanzee resilience	4
Canonical and non-canonical roles of complement in atherosclerosis	4
Safety of paclitaxel-coated devices in peripheral artery disease	4
Anti-IL-1β therapy lowers leukocyte supply and uptake in atherosclerosis	4
Publisher Correction: Cardiac involvement in the long-term implications of COVID-19	4
A call for training programmes in cardiovascular genomics	4
Global epidemiology of heart failure	4
Clonal haematopoiesis induces a pro-inflammatory monocyte phenotype in HF	4
Diversity in human genetics studies accelerates discovery and improves health care	4
Carotid stenosis management: time to address the misconceptions (‘furphies’)	4
Inflammation in plaque erosion and rupture	4
Machine learning predicts risk in ACS	4
Promising anti-IL-6 therapy for atherosclerosis	4
Boosting mitochondrial metabolism with dietary supplements in heart failure	4
Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved	4
Prehabilitation: evolving role in contemporary cardiac surgery	3
Macrophages promote endothelial-to-mesenchymal transition after MI	3
Iron deficiency and supplementation in heart failure	3
Improving the cardiovascular health care of transgender and non-binary persons	3
Immune checkpoint inhibitors: acute and chronic cardiovascular complications	3
Hydralazine reduces myocardial infarct size	3
Sotatercept therapy for PAH	3
Are blood-pressure targets needed to prevent cardiovascular disease?	3
Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects	3
Glucocorticoid receptor inhibition promotes cardiac repair after MI	3
Targeted therapies for cardiac diseases	3
Limited benefit of triglyceride lowering with fibrates in statin-treated patients	3
Artificial sweetener linked to higher CVD risk	3
Reduced lymphatic drainage promotes HFpEF and atherosclerosis	3
Age-related loss of Y chromosome in leukocytes linked to cardiac fibrosis	3
Graded exercise therapy should not be recommended for patients with post-exertional malaise	3
Hyperglycaemia-induced trained immunity promotes atherosclerosis	3
Autoimmune diseases and atherosclerotic cardiovascular disease	3
Modulating the gut microbiota with dietary interventions to protect against cardiometabolic disease	3
Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention	3
The role of the molecular autopsy in sudden cardiac death in young individuals	3
Socioeconomic inequalities in cardiovascular disease: a causal perspective	3
Not a spectator sport: improving participation of Black patients in cardiovascular clinical trials	3
Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease	3
Early inhibition of IL-6 signalling after an acute MI improves myocardial salvage	3